NCT02224391

Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking

Smartphone-Delivered Attentional Bias Modification Training for Quitting Smokers

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 311 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This randomized clinical trial studies how well a smartphone-delivered attentional bias modification training works in helping patients quit smoking. Smartphone-delivered attentional bias modification training may help patients quit smoking by reducing the attentional bias (the tendency of one's perception to be affected by their recurring thoughts) towards smoking cues that developed over time as a result of conditioning processes through which smoking cues become important.

Detailed description

PRIMARY OBJECTIVES: I. To determine the feasibility of smartphone-delivered, in-home attentional bias modification (ABM) to reduce attentional bias (AB) to smoking cues and to reduce smoking behavior in the short- and long-term. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks. ARM II: Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks. After completion of study treatment, patients are followed up on days 15, 29, 43, 57, and 72.

Conditions

• Current Every Day Smoker

Interventions

Type	Name	Description
BEHAVIORAL	Computer-Assisted Smoking Cessation Intervention	Receive ABM training via a smartphone
OTHER	Laboratory Biomarker Analysis	Correlative studies
DRUG	Nicotine Patch	Given via transdermal patch
OTHER	Questionnaire Administration	Ancillary studies
OTHER	Sham Intervention	Undergo sham training

Timeline

• Start date: 2016-01-20
• Primary completion: 2021-03-15
• Completion: 2021-03-15
• First posted: 2014-08-25
• Last updated: 2023-03-07
• Results posted: 2022-09-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study